Japan to Cut Price of Alzheimer’s Drug Lecanemab by 15%

Lifestyle | Health & Family Posted on 2025-08-11 18:38:55

TOKYO – Japan’s health ministry has approved a 15% price cut for Lecanemab, an Alzheimer’s drug co-developed by Eisai Co. and US partner Biogen Inc., effective November 1.

The Central Social Insurance Medical Council recommended the reduction after finding the drug’s cost-effectiveness to be low relative to its price. The cost of a 500-milligram bottle will drop to 97,277 yen, with dosages determined by patient weight.

For instance, treatment for a 50-kilogram patient will decrease from about 2.98 million yen to roughly 2.53 million yen annually.

Lecanemab, considered innovative for removing abnormal brain proteins linked to Alzheimer’s, is designed to slow disease progression. The drug’s price is regulated under Japan’s cost-effectiveness adjustment system for high-priced or high-demand medicines.

NPO News Team

PNA-PR

Writer :

Link :